Recro Pharma, Inc. (REPH)
(Delayed Data from NSDQ)
$9.00 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[REPH]
Reports for Purchase
Showing records 1 - 20 ( 69 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
We are dropping coverage to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
IV Meloxicam Receives CRL - Downgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
3Q18 Recap: Manufacturing Strong; PDUFA of March 24 for IV Meloxicam
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.